June 22, 2011 - ZOLL LifeVest to be Showcased at EHRA Europace 2011


Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637


Wearable Defibrillator to be Discussed in Three Posters at Scientific Sessions

June 22, 2011 - CHELMSFORD, MASS. - ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of medical devices and related software solutions, today announced that it will display the LifeVest® Wearable Defibrillator in Booth D10 at the European Heart Rhythm Association (EHRA) Europace 2011, being held from 26-29 June in Madrid, Spain. The LifeVest will be discussed during three scientific/educational poster presentations.

These LifeVest presentations include:

  • Joann Glad, Dr.PH, ZOLL, will present “Incidence of inappropriate wearable defibrillator shocks is rare­­­­­­—an evaluation of 15,193 wearable defibrillator patients,” Monday, 27 June, 8:30 a.m., Poster Area – Poster Session 1: P375.
  • Steve Szymiewicz, M.D., ZOLL, will present “Sudden cardiac arrest survival in patients wearing a wearable defibrillator: Geographic location does not impact survival success,” Tuesday, 28 June, 14:00 p.m., Poster Area – Poster Session 4: P1203.
  • Dr. Glad will also present “Survival outcomes for post shock asystole in patients wearing a wearable defibrillator,” Tuesday, 28 June, 14:00 p.m., Poster Area – Poster Session 4: P1204.

The LifeVest is worn by patients at risk for sudden cardiac arrest (SCA), providing protection during their changing condition and while permanent SCA risk has not been established. The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA.  The LifeVest continuously monitors the patient’s heart. If a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.

“In Europe, it is estimated that over 350,000 individuals experience sudden cardiac arrest each year,” said Richard A. Packer, Chief Executive Officer of ZOLL. Timely defibrillation is the single most important factor in saving a cardiac arrest victim’s life.  The LifeVest therapy provides continuous protection for the high risk patient without requiring bystander intervention. The LifeVest has a 98 percent first treatment shock success rate for resuscitating patients from sudden cardiac arrest.”  

The LifeVest is used for a wide range of patient conditions, including following a heart attack, before or after bypass surgery or stent placement, as well as cardiomyopathy or congestive heart failure that places patients at particular risk.

To date, the LifeVest has been prescribed for over 40,000 patients.

About ZOLL Medical Corporation

ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company in 2007, 2008, and 2009, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.

Copyright © 2011 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105.  LifeVest and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. All product names are the property of their respective owners.